E-ISSN 2537-0596 | ISSN 2537-0588
 

Mini Review 


The therapeutic efficacy for targeting the PI3K signaling pathway for fighting breast, prostate and multiple myeloma cancer cells

Badr Mohamed Badr, Gamal Badr.

Abstract
The PI3K signaling pathway is involved in the regulation of cancer cell growth, motility, survival and metabolism. This pathway is frequently active in many different types of cancer as breast, prostate and multiple myeloma. Targetable genetic aberrations in this pathway give the researchers many opportunities for the development of targeted therapies for different types of cancer. The high frequency of mutations in this pathway in multiple types of cancer has led to the development of small-molecule inhibitors of PI3K, several of which are currently in clinical trials. However, several feedback mechanisms either within the PI3K pathway or in compensatory pathways can render tumor cells resistant to therapy. Here, we give insight into the importance of the PI3K pathway as a target for cancer therapy and discuss the potential clinical efficacy of PI3K inhibitors. We mainly focused on the roles of PI3K signaling pathway in three cancer cell types including breast cancer, prostate cancer and multiple myeloma cancer.

Key words: PI3K; AKT; mTOR; breast cancer; prostate cancer; multiple myeloma.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Badr Mohamed Badr
Articles by Gamal Badr
on Google
on Google Scholar
Article Statistics
 Viewed: 584
Downloaded: 35
Cited: 0

How to Cite this Article
Pubmed Style

Badr BM, Badr G. The therapeutic efficacy for targeting the PI3K signaling pathway for fighting breast, prostate and multiple myeloma cancer cells. JCBR. 2019; 1(2): 37-43.


Web Style

Badr BM, Badr G. The therapeutic efficacy for targeting the PI3K signaling pathway for fighting breast, prostate and multiple myeloma cancer cells. http://www.jcbreg.com/?mno=298139 [Access: March 26, 2019].


AMA (American Medical Association) Style

Badr BM, Badr G. The therapeutic efficacy for targeting the PI3K signaling pathway for fighting breast, prostate and multiple myeloma cancer cells. JCBR. 2019; 1(2): 37-43.



Vancouver/ICMJE Style

Badr BM, Badr G. The therapeutic efficacy for targeting the PI3K signaling pathway for fighting breast, prostate and multiple myeloma cancer cells. JCBR. (2019), [cited March 26, 2019]; 1(2): 37-43.



Harvard Style

Badr, B. M. & Badr, . G. (2019) The therapeutic efficacy for targeting the PI3K signaling pathway for fighting breast, prostate and multiple myeloma cancer cells. JCBR, 1 (2), 37-43.



Turabian Style

Badr, Badr Mohamed, and Gamal Badr. 2019. The therapeutic efficacy for targeting the PI3K signaling pathway for fighting breast, prostate and multiple myeloma cancer cells. Journal of Cancer and Biomedical Research, 1 (2), 37-43.



Chicago Style

Badr, Badr Mohamed, and Gamal Badr. "The therapeutic efficacy for targeting the PI3K signaling pathway for fighting breast, prostate and multiple myeloma cancer cells." Journal of Cancer and Biomedical Research 1 (2019), 37-43.



MLA (The Modern Language Association) Style

Badr, Badr Mohamed, and Gamal Badr. "The therapeutic efficacy for targeting the PI3K signaling pathway for fighting breast, prostate and multiple myeloma cancer cells." Journal of Cancer and Biomedical Research 1.2 (2019), 37-43. Print.



APA (American Psychological Association) Style

Badr, B. M. & Badr, . G. (2019) The therapeutic efficacy for targeting the PI3K signaling pathway for fighting breast, prostate and multiple myeloma cancer cells. Journal of Cancer and Biomedical Research, 1 (2), 37-43.